Post-effective Amendment to an S-8 Filing (s-8 Pos)
29 Março 2016 - 3:50PM
Edgar (US Regulatory)
As filed with the Securities and Exchange Commission on March 29, 2016
Registration No. 333-197279
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
POST-EFFECTIVE AMENDMENT NO. 1
TO
FORM S-8
REGISTRATION STATEMENT
UNDER
THE
SECURITIES ACT OF 1933
BG MEDICINE, INC.
(Exact Name of Registrant as Specified in Its Charter)
|
|
|
|
|
Delaware
|
|
04-3506204
|
|
(State or Other Jurisdiction of
Incorporation or Organization)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
|
|
303 Wyman Street, Suite 300, Waltham, Massachusetts
|
|
02451
|
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
BG MEDICINE, INC. 2010 EMPLOYEE, DIRECTOR AND CONSULTANT STOCK PLAN
BG MEDICINE, INC. 2010 EMPLOYEE STOCK PURCHASE PLAN
(Full Titles of the Plans)
Paul R. Sohmer, M.D.
President and Chief Executive Officer
BG Medicine, Inc.
303
Wyman Street, Suite 300
Waltham, Massachusetts 02451
(781) 890-1199
(Name,
Address and Telephone Number, Including Area Code, of Agent for Service)
Copies to:
William T. Whelan, Esq.
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
One Financial Center
Boston, Massachusetts 02111
(617) 542-6000
Facsimile: (617) 542-2241
Indicate by check mark whether
the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting
company” in Rule 12b-2 of the Exchange Act.
|
|
|
|
|
|
|
|
|
Large accelerated filer
|
|
¨
|
|
Accelerated filer
|
|
¨
|
|
|
|
|
|
|
Non-accelerated filer
|
|
¨
(Do not check if a smaller reporting company)
|
|
Smaller reporting company
|
|
x
|
DEREGISTRATION OF UNSOLD SECURITIES
The Registrant is filing this Post-Effective Amendment No. 1 (“Post-Effective Amendment”) to the Registration Statement on Form
S-8 (Registration No. 333-197279), filed on July 7, 2014, which registered an aggregate of 494,990 shares of common stock issuable to participants in the Registrant’s 2010 Employee, Director and Consultant Stock Plan and 2010 Employee
Stock Purchase Plan. In accordance with an undertaking made by the Registrant in the Registration Statement to remove from registration, by means of a post-effective amendment, any of the securities registered under the Registration Statement which
remain unsold at the termination of the offering, the Registrant hereby amends the Registration Statement to deregister any remaining securities registered and unsold under the Registration Statement. The securities are being removed from
registration because the securities are no longer being offered or sold pursuant to the Registration Statement.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the
requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment No. 1 to its Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Waltham, State of Massachusetts
on March 29, 2016.
|
|
|
|
|
|
|
BG MEDICINE, INC.
|
|
|
|
|
By:
|
|
/s/ Paul R. Sohmer, M.D.
|
|
|
|
Paul R. Sohmer, M.D.
|
|
|
|
President and Chief Executive Officer
|
Pursuant to the requirements of the Securities Act of 1933, this Post-Effective Amendment No. 1 to the Registration
Statement has been signed by the following persons in the capacities and on the dates indicated.
|
|
|
|
|
|
|
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/ Paul R. Sohmer, M.D.
|
|
President, Chief Executive Officer and Director (principal executive officer)
|
|
March 29, 2016
|
|
Paul R. Sohmer, M.D.
|
|
|
|
|
|
|
|
/s/ Stephen P. Hall
Stephen P. Hall
|
|
Executive Vice President, Chief Financial Officer and Treasurer (principal financial officer and principal accounting officer)
|
|
March 29, 2016
|
|
|
|
|
|
|
|
|
/s/ Jeffrey R. Luber
|
|
Director
|
|
March 29, 2016
|
|
Jeffrey R. Luber
|
|
|
|
|
|
|
|
/s/ James F. O’Connor
|
|
Director
|
|
March 29, 2016
|
|
James F. O’Connor
|
|
|
|
|
|
|
|
/s/ Stelios Papadopoulos, Ph.D.
|
|
Director, Vice Chairman of the Board
|
|
March 29, 2016
|
|
Stelios Papadopoulos, Ph.D.
|
|
|
|
|
|
|
|
/s/ Harry W. Wilcox
|
|
Director, Chairman of the Board
|
|
March 29, 2016
|
|
Harry W. Wilcox
|
|
|
BG Medicine (CE) (USOTC:BGMD)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
BG Medicine (CE) (USOTC:BGMD)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024
